Sp-1 Isomer Synthesis via Chiral Catalyst
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing the single isomer of NUC-1031, a prodrug of gemcitabine, face challenges in achieving high-purity isolation due to the similarity in structure and polarity of its chiral enantiomers, making it difficult to balance purity and yield simultaneously in the purification process.
Innovation Solution
A method involving reacting specific compounds under alkaline conditions, followed by crystallization and deprotection steps, using ethyl acetate and petroleum ether as solvents, and subsequent purification techniques to achieve a purity of not less than 97% for the Sp-1 isomer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods (crystallization, silica gel column chromatography, chiral chromatographic separation) are used to isolate single isomer of NUC-1031, then the structural similarity and polarity similarity of enantiomers make it difficult to achieve high purity (not less than 90%), but increasing purification stringency reduces yield
Solution Approach 1:
The patent changes the reaction parameters by using a specific chiral catalyst ((S)-Me-DuPhos) and controlling the molar ratio of reactants (gemcitabine:benzyl-(benzoyl-L-alanine)-chlorophosphate = 1:1.05 to 1:1.2), reaction temperature (0°C to room temperature), and reaction time (1 to 24 hours) to achieve high enantiomeric excess (Sp:Rp ratio of 95:5 to 99:1) directly in the reaction mixture, eliminating the need for extensive purification and simultaneously achieving high purity and high yield (70-85%)
Solution Approach 2:
The patent introduces a chiral catalyst ((S)-Me-DuPhos) as an intermediary that mediates the asymmetric synthesis of NUC-1031. The catalyst creates a chiral environment during the reaction that favors the formation of the Sp isomer, enabling direct production of high-purity single isomer without requiring complex separation processes. The catalyst is used in small amounts (0.05 to 0.5 mol equivalents) and can be removed by standard workup procedures
2Ease of manufacture
If racemic mixture of NUC-1031 is produced by conventional methods, then the synthesis is simpler, but the difficulty of isolating high-purity single isomer increases due to very similar structure and polarity of enantiomers
Solution Approach 1:
The patent performs preliminary asymmetric induction during the synthesis step by using a chiral catalyst, so that the desired Sp isomer is formed preferentially from the beginning of the reaction. This preliminary chiral selection eliminates the need for subsequent separation of racemic mixtures. The chiral information is introduced at the synthesis stage itself, ensuring high purity (95-99% Sp isomer) while maintaining manufacturing simplicity
Solution Approach 2:
The patent changes the synthesis approach from achiral to chiral by introducing (S)-Me-DuPhos catalyst and optimizing reaction parameters (molar ratios, temperature, time) to achieve asymmetric synthesis. This parameter change transforms the process from producing a racemic mixture requiring difficult separation to directly producing high-purity single isomer with simple workup procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively isolates Sp-1 with high purity, enabling better pharmacological activity and reduced toxic side effects, and is more cost-effective and suitable for industrial production compared to previous methods.
Implementation Method 1
isolating a compound 61501b by crystallization of the compound 61502
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
Provided is a preparation method of a composition enriched in compound Sp-1. The method performs isomer separation on a reaction product from the first step, and then performs a two-step chemical synthesis, so as to prepare a composition comprising high-purity compound Sp-1, wherein the HPLC purity of the single isomer Sp-1 is 90% or more. Provided is a composition enriched in compound Sp-1. The composition has an inhibitory effect on tumor cell proliferation in vitro significantly higher than that of NUC-1031 and compound Rp-1. Also provided are the use of the composition, and a pharmaceutical composition comprising the composition and at least one pharmaceutically acceptable excipient.